These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 10837568)

  • 1. Therapeutic effects of leuprorelin microspheres in prostate cancer.
    Lee M; Browneller R; Wu Z; Jung A; Ratanawong C; Sharifi R
    Adv Drug Deliv Rev; 1997 Oct; 28(1):121-138. PubMed ID: 10837568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Leuprorelin acetate in prostate cancer: a European update.
    Persad R
    Int J Clin Pract; 2002 Jun; 56(5):389-96. PubMed ID: 12137449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Testosterone suppression with a unique form of leuprorelin acetate as a solid biodegradable implant in patients with advanced prostate cancer: results from four trials and comparison with the traditional leuprorelin acetate microspheres formulation.
    Solarić M; Bjartell A; Thyroff-Friesinger U; Meani D
    Ther Adv Urol; 2017 Dec; 9(6):127-136. PubMed ID: 28588651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer.
    Kunath F; Grobe HR; Rücker G; Motschall E; Antes G; Dahm P; Wullich B; Meerpohl JJ
    Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD009266. PubMed ID: 24979481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical study results of the new formulation leuprorelin acetate three-month depot for the treatment of advanced prostate carcinoma.
    Fornara P; Jocham D
    Urol Int; 1996; 56 Suppl 1():18-22. PubMed ID: 8776813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical development of two innovative pharmaceutical forms of leuprorelin acetate.
    Geiges G; Schapperer E; Thyroff-Friesinger U; Engert ZV; Gravel P
    Ther Adv Urol; 2013 Feb; 5(1):3-10. PubMed ID: 23372606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of LH-RH analogue 1-month depot and 3-month depot by their hormone levels and pharmacokinetic profile in patients with advanced prostate cancer.
    Tunn UW; Bargelloni U; Cosciani S; Fiaccavento G; Guazzieri S; Pagano F
    Urol Int; 1998; 60 Suppl 1():9-16; discussion 16-7. PubMed ID: 9563139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An evaluation of pharmacokinetics and pharmacodynamics of leuprorelin acetate 3M-depot in patients with advanced and metastatic carcinoma of the prostate.
    Khan MS; O'Brien A
    Urol Int; 1998; 60(1):33-40. PubMed ID: 9519419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Leuprorelin. A review of its pharmacology and therapeutic use in prostatic cancer, endometriosis and other sex hormone-related disorders.
    Plosker GL; Brogden RN
    Drugs; 1994 Dec; 48(6):930-67. PubMed ID: 7533699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Leuprorelin. A review of its pharmacology and therapeutic use in prostatic disorders.
    Chrisp P; Sorkin EM
    Drugs Aging; 1991; 1(6):487-509. PubMed ID: 1794035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of a new leuprorelin formulation on testosterone levels in patients with advanced prostate cancer.
    Berges R; Bello U
    Curr Med Res Opin; 2006 Apr; 22(4):649-55. PubMed ID: 16684425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical pharmacokinetics of depot leuprorelin.
    Periti P; Mazzei T; Mini E
    Clin Pharmacokinet; 2002; 41(7):485-504. PubMed ID: 12083977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New treatment paradigm for prostate cancer: abarelix initiation therapy for immediate testosterone suppression followed by a luteinizing hormone-releasing hormone agonist.
    Garnick MB; Mottet N
    BJU Int; 2012 Aug; 110(4):499-504. PubMed ID: 22093775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimal starting time for flutamide to prevent disease flare in prostate cancer patients treated with a gonadotropin-releasing hormone agonist.
    Tsushima T; Nasu Y; Saika T; Maki Y; Noda M; Suyama B; Yamato T; Kumon H
    Urol Int; 2001; 66(3):135-9. PubMed ID: 11316974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of combination therapy with a luteinizing hormone-releasing hormone agonist and chlormadinone acetate on rat prostate weight and plasma testosterone levels.
    Gotanda K; Shinbo A; Okada M; Nakano Y; Kobayashi H; Sasaki T; Hagiwara M; Akaza H
    Prostate Cancer Prostatic Dis; 2003; 6(1):66-72. PubMed ID: 12664069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-steroidal antiandrogen monotherapy compared with luteinizing hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer: a Cochrane systematic review.
    Kunath F; Grobe HR; Rücker G; Motschall E; Antes G; Dahm P; Wullich B; Meerpohl JJ
    BJU Int; 2015 Jul; 116(1):30-6. PubMed ID: 25523493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Goserelin acetate implant: a depot luteinizing hormone-releasing hormone analog for advanced prostate cancer.
    Goldspiel BR; Kohler DR
    DICP; 1991; 25(7-8):796-804. PubMed ID: 1835221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and tolerability of 1- and 3-month leuprorelin acetate depot formulations (Eligard(®)/Depo-Eligard(®)) for advanced prostate cancer in daily practice: a Belgian prospective non-interventional study.
    Braeckman J; Michielsen D
    Arch Med Sci; 2014 Jun; 10(3):477-83. PubMed ID: 25097577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preliminary clinical evaluation of leuprorelin acetate depot injection in France, in the management of prostatic cancer.
    Navratil H
    J Int Med Res; 1990; 18 Suppl 1():69-73. PubMed ID: 2108887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is the flare phenomenon clinically significant?
    Bubley GJ
    Urology; 2001 Aug; 58(2 Suppl 1):5-9. PubMed ID: 11502435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.